Resistance to endocrine therapy in patients with ER+ breast cancer represents a significant clinical challenge, often leading to treatment failure and poor prognostic outcomes (Portman et al., 2019; Ferro et al., 2024). Here, ESR1 is linked to breast carcinoma.